Back

Safety and tolerability of sacubitril/valsartan in chronic heart failure and reduced ejection fraction: results from the open-label extension of PARADIGM-HF

21 May 2023 (13:00 - 13:45)
Organised by: Logo
Congress Presentation Part of: Heart failure with reduced ejection fraction (HFrEF) 2 Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Professor Michele Senni

Papa Giovanni XXIII Hospital, Bergamo (Italy)

7 More presentations in this session

Presentation thumbnail
The usefulness of end-expiratory oxygen partial pressure as a prognostic indicator in patients with heart failure with reduced ejection fraction
Doctor T. Nakade (Tokyo, JP)
Abstract Slides
Presentation thumbnail
SGLT2 inhibitors in heart failure with reduced ejection fraction without diabetes mellitus: why are patients outside the magic circle?
Doctor D. Santoro (Pavia, IT)
Abstract Slides
Presentation thumbnail
Integrated transcriptomic and regulatory RNA sequencing and machine-learning driven analyses identify molecular signatures underlying human heart failure
Doctor J. Gulia (Bengaluru, IN)
Abstract Slides
Presentation thumbnail
Impact of prolonged use of angiotensin receptor-neprilysin inhibitors versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with heart failure reduced ejection frac
Assistant Professor B. PARK (Daegu, KR)
Abstract Slides
Presentation thumbnail
Cardiac amyloidosis patients with reduced ejection fraction have an increase morbimortality
Doctor F. Bauer (Le Kremlin-Bicetre, FR)
Abstract Slides

Access the full session

Session thumbnail
Heart failure with reduced ejection fraction (HFrEF) 2

The Event

Event poster

Heart Failure 2023

21 May 2023 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Is sacubitril/valsartan well tolerated in elderly heart failure patients with reduced ejection fraction? Preliminary data from a real-word registry.
29 June 2021
thumbnail
Congress Presentation
Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study
31 August 2019
thumbnail
Congress Presentation
Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
28 August 2020
thumbnail
Congress Presentation
Duration of heart failure with preserved ejection fraction and treatment with sacubitril/valsartan: insights from the PARAGON-HF trial
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources